Cullinan Therapeutics (CGEM): State Street discloses 3.67M-share, 6% ownership stake
Rhea-AI Filing Summary
State Street Corporation reported beneficial ownership of common stock of Cullinan Therapeutics Inc. on a Schedule 13G. State Street beneficially owns 3,668,627 shares of common stock, representing 6% of the class. These shares are held with shared voting power over 3,565,748 shares and shared dispositive power over 3,668,627 shares, with no sole voting or dispositive power. The filing attributes the holdings to asset management subsidiaries including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd.
Positive
- None.
Negative
- None.
Key Figures
Beneficial ownership: 3,668,627 shares
Percent of class: 6 %
Shared voting power: 3,565,748 shares
+3 more
6 metrics
Beneficial ownership
3,668,627 shares
Amount of Cullinan Therapeutics common stock beneficially owned by State Street Corporation
Percent of class
6 %
Percentage of Cullinan Therapeutics common stock class beneficially owned
Shared voting power
3,565,748 shares
Shares over which State Street has shared power to vote or direct the vote
Sole voting power
0 shares
Shares over which State Street has sole power to vote or direct the vote
Shared dispositive power
3,668,627 shares
Shares over which State Street has shared power to dispose or direct disposition
Sole dispositive power
0 shares
Shares over which State Street has sole power to dispose or direct disposition
Key Terms
beneficially owned, shared voting power, shared dispositive power, parent holding company, +1 more
5 terms
beneficially owned financial
"Item 4. | Ownership (a) | Amount beneficially owned: 3668627.00"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
parent holding company financial
"If a parent holding company has filed this schedule, pursuant to (ii)(G)"
investment company financial
"A listing of the shareholders of an investment company registered under the Investment Company Act of 1940"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How much of Cullinan Therapeutics (CGEM) stock does State Street Corporation own?
State Street Corporation reported beneficial ownership of 3,668,627 shares of Cullinan Therapeutics common stock, representing 6% of the outstanding class, with all voting and dispositive authority held on a shared basis through its investment management subsidiaries.
Which subsidiaries of State Street are associated with its Cullinan Therapeutics (CGEM) holdings?
The holdings are associated with SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd., each classified as an investment adviser.
Does any other person have rights to proceeds from State Street’s Cullinan Therapeutics (CGEM) stake?
The filing states “NOT APPLICABLE” in response to whether any other person is known to have the right to receive dividends or sale proceeds from the reported Cullinan Therapeutics securities, indicating no such party is specifically identified.
Why did State Street file a Schedule 13G for Cullinan Therapeutics (CGEM)?
A Schedule 13G is filed to report beneficial ownership of more than 5% of a class of equity securities. State Street filed because its affiliated investment advisers collectively beneficially own 6% of Cullinan Therapeutics’ common stock.